# Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

> **NCT01109069** · PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 199 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Diffuse Well-differentiated Lymphocytic Lymphoma
- B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Non-Hodgkin's Lymphoma
- Waldenstrom Macroglobulinemia
- Burkitt Lymphoma
- B-Cell Diffuse Lymphoma

## Interventions

- **DRUG:** PCI-32765

## Key facts

- **NCT ID:** NCT01109069
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2020-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109069, "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01109069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*